NCT04789954View on ClinicalTrials.gov

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

August 13, 2021

Study Completion Date

July 31, 2022

Conditions
Hemophilia A With InhibitorHemophilia B With Inhibitor
Interventions
BIOLOGICAL

Eptacog alfa, activated

A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.

Trial Locations (1)

Unknown

Comprehensive Hemophilia Care Center, Tehran

Sponsors
All Listed Sponsors
lead

AryoGen Pharmed Co.

INDUSTRY